HCA Healthcare (HCA)
Salud / Servicios hospitalarios
The largest private hospital operator in the United States, with 190 hospitals and a buyback machine that retires close to 5% of the share count per year. At ~$428 (15× normalized attributable net income, 25% below the 52-week high after the July 2026 guidance cut), 5-year base ~$580 (+6%/year price, +7% with dividend): Fairly valued — the return depends on the 2026 regulatory hit being a level shift, not a trend.
- Price
- $428.04
- Intrinsic value (5y, base)
- $580
- Total annual return (5y)
- 7.1%
- Status (nominal)
- Fairly valued
- Margin of safety
- +11%
The essentials
- Real scale: 190 hospitals and 121 freestanding surgery centers across 19 states and England, with 320,000 employees. Texas and Florida account for 51% of revenue, with 102 of the 190 hospitals — local density that is both the source of the advantage and the concentration of risk.
- The engine of per-share value is the buyback: diluted shares fell from 294.7 million in 2022 to 226.7 in the first quarter of 2026, close to 6% annually, with $10,067 million spent in 2025. Aggregate net income grows much less than earnings per share.
- 2026 brings an identified and bounded regulatory hit: guidance revised on July 14, 2026 cut the ceiling on attributable net income to $6,300-6,700 million, due to the expiration of enhanced premium tax credits for individual market health insurance exchanges (impact of $1,000 to $1,200 million) partially offset by Medicaid supplemental programs ($300 to $500 million favorable).
- Leverage is the counterpart: $48,023 million of total debt against negative book equity of $6,303 million. The debt is the deliberate result of financing buybacks, not of operating deterioration, but it leaves little room if cash flow compresses.
Intrinsic value — two valuation methods
Total return at 5 years: 7.1%/year = 6.3% appreciation + 0.8% dividend. The target price ($580) is ex-dividend; the $19 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $799 · Multiples $482) exceeds the market price ($428).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $428 trades ~11.2% below its value discounted to today (~$482); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — En valor: the target price ($580) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$301.
Thesis
The business
HCA is the largest private hospital operator in the United States and a high-return business on a depressed book equity: trailing-twelve-month operating income runs around $12,100 million on revenue of $78,013 million, with a return on invested capital well above the 10% hurdle. The moat is local and real, but it is narrowing: site-neutral payment and the migration of procedures to the outpatient setting pull higher-margin volume away from the traditional hospital.
The valuation
A hospital operator is valued on an earnings multiple, with the method's reference band at 9 to 13 times. Here it is applied to net income attributable to HCA rather than to consolidated net income, because the non-controlling interest is material: $1,020 million out of $6,794 million of trailing-twelve-month consolidated net income, or 15%, from the joint ventures through which HCA operates many hospitals. The company's guidance is expressed on that same basis.
The base case starts from the two anchors of the guidance revised on July 14, 2026 (revenue of $77.0 to $79.5 billion and attributable net income of $6.3 to $6.7 billion), goes through a nearly flat year 1, and from there recovers to durable growth of ~5% with net margin returning from 8.3% to 9.0%. With the multiple compressing from 15× to 12 times and the buyback retiring close to 4% of shares per year, the five-year value is ~$580 per share, or +6% annual price return and +7% including the dividend.
The margin of safety
It trades close to intrinsic value, far from the required margin of safety. The bear case (+7%) assumes that the loss of individual-market enrollees does not lap but instead accumulates with the cut to Medicaid supplemental programs starting in 2028, and there net margin falls to 7.5% with the multiple at the floor of the band; the bull case (+7%) assumes the hit is a single-year event and that operating leverage pushes the margin back above 9.5%. The gap between the two extremes is wide precisely because leverage amplifies any move in the margin: $48,023 million of debt against negative book equity.
What to watch
The disconfirming test is the payer mix. Uninsured admissions and uncompensated care need to be tracked quarter by quarter: if the expiration of the enhanced premium tax credits pushes that curve faster than the company guided, the margin compresses before volume can offset it. The second gauge is the calendar of the Medicaid directed and supplemental payment programs, which contributed $6,200 million of revenue in 2025 and whose grandfathering protection starts to be limited in 2028.
Educational / informational. Does not constitute investment advice.